← Russell 3000 cross-section

CTKB Cytek Biosciences, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$607m
Revenue TTM
$207m
Net income TTM
$-81m
Free cash flow
$-12m
Composite score
47.1
Sector rank
#2301

Valuation

P / E
EV / EBITDA
EV / sales
2.6
FCF yield
-1.99%
Earnings yield vs 10-yr
-18.01pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-39.0%
EBITDA margin
-17.9%
ROE
-25.0%
ROIC
-18.0%
Revenue growth
5.4%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Total revenue for the three and six months ended June 30, 2026 was $48.1 million and $92.3 million, respectively, representing a 6% increase in revenue for both the three and six months ended June 30, 2025 of $45.6 million and $87.1 million, respectively. Revenue from direct sales represented 69% and 69% of total revenue for the three and six months ended June 30, 2026, respectively, and 73% and 73% of total revenue for the three and six months ended June 30, 2025, respectively. …Cytek Biosciences, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →